|
US5120722A
(en)
|
1984-02-08 |
1992-06-09 |
Hoffmann-La Roche Inc. |
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
|
|
US4857518A
(en)
|
1984-10-04 |
1989-08-15 |
Wisconsin Alumni Research Foundation |
Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
|
|
US4717721A
(en)
|
1985-05-30 |
1988-01-05 |
Howard W. Bremer |
Sidechain homo-vitamin D compounds with preferential anti-cancer activity
|
|
EP0227826B1
(en)
|
1985-08-02 |
1989-10-25 |
Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) |
Novel vitamin d analogues
|
|
US5145846A
(en)
|
1988-01-20 |
1992-09-08 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
|
US4851401A
(en)
|
1988-07-14 |
1989-07-25 |
Wisconsin Alumni Research Foundation |
Novel cyclopentano-vitamin D analogs
|
|
CA1333616C
(en)
|
1989-03-09 |
1994-12-20 |
Hector F. Deluca |
19-nor-vitamin d compounds
|
|
GB8915770D0
(en)
|
1989-07-10 |
1989-08-31 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US4966898A
(en)
|
1989-08-15 |
1990-10-30 |
Merrell Dow Pharmaceuticals Inc. |
4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
|
|
DE4021433A1
(de)
|
1990-07-04 |
1992-01-09 |
Schering Ag |
Antiandrogene mit steroid(3,2-c)pyrazol-struktur
|
|
DE4101953A1
(de)
|
1991-01-19 |
1992-07-23 |
Schering Ag |
23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
|
|
DE4141746A1
(de)
|
1991-12-13 |
1993-06-17 |
Schering Ag |
20-methyl-substituierte vitamin d-derivate
|
|
WO1993020097A1
(en)
|
1992-03-31 |
1993-10-14 |
British Technology Group Ltd. |
17-substituted steroids useful in cancer treatment
|
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
|
US5547947A
(en)
|
1993-03-11 |
1996-08-20 |
Hoffmann-La Roche Inc. |
Methods of treatment
|
|
SG49321A1
(en)
|
1993-09-30 |
1998-05-18 |
British Tech Group |
Synthesis of 17-(3-pyridyl) steroids
|
|
US5688977A
(en)
|
1996-02-29 |
1997-11-18 |
Napro Biotherapeutics, Inc. |
Method for docetaxel synthesis
|
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
JP4172726B2
(ja)
|
1996-05-22 |
2008-10-29 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
|
|
US5919815A
(en)
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
|
GB9622590D0
(en)
|
1996-10-30 |
1997-01-08 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US6087350A
(en)
|
1997-08-29 |
2000-07-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
|
|
US6521608B1
(en)
|
1998-03-27 |
2003-02-18 |
Oregon Health & Science University |
Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
|
|
US20030083231A1
(en)
|
1998-11-24 |
2003-05-01 |
Ahlem Clarence N. |
Blood cell deficiency treatment method
|
|
IL143901A0
(en)
|
1998-12-23 |
2002-04-21 |
Searle & Co |
Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
|
|
ATE383863T1
(de)
|
2000-03-02 |
2008-02-15 |
Univ Pittsburgh |
Kombinationschemotherapie
|
|
JPWO2001081364A1
(ja)
|
2000-04-24 |
2004-01-08 |
協和醗酵工業株式会社 |
エストラ−１，３，５（１０）−トリエン誘導体
|
|
EP1676577A1
(en)
|
2000-05-15 |
2006-07-05 |
Celgene Corporation |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
|
|
KR100790589B1
(ko)
|
2000-05-15 |
2008-01-02 |
셀겐코포레이션 |
암 치료용 조성물 및 치료 방법
|
|
AU2001275423B2
(en)
|
2000-06-09 |
2007-01-11 |
Regulon, Inc. |
Encapsulation of polynucleotides and drugs into targeted liposomes
|
|
AU2000260772A1
(en)
|
2000-07-05 |
2002-01-14 |
Bryan Muehlberger |
Systems and methods of facilitating electronic payment transactions
|
|
US6960590B2
(en)
|
2000-10-17 |
2005-11-01 |
Merck & Co. Inc. |
Orally active salts with tyrosine kinase activity
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
DE10061137B4
(de)
|
2000-12-07 |
2016-10-06 |
Takeda Gmbh |
Neue pharmazeutische Zubereitung
|
|
WO2002053138A2
(en)
|
2001-01-02 |
2002-07-11 |
Elisabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
SI1385514T1
(sl)
|
2001-04-18 |
2009-04-30 |
Euro Celtique Sa |
Spiroindenske in spiroindanske spojine
|
|
PT1975164E
(pt)
|
2001-04-18 |
2010-04-20 |
Euro Celtique Sa |
Compostos de octa-hidrobenzimidazolona utilizados como analgésicos
|
|
JP4342181B2
(ja)
|
2001-04-18 |
2009-10-14 |
ユーロ−セルティーク エス．エイ． |
スピロピラゾール化合物
|
|
DK1598339T3
(da)
|
2001-04-18 |
2009-09-28 |
Euro Celtique Sa |
1-(4-amino-cyclohexyl)-1,3-dihydro-2H-benzimidazol-2-on derivater og beslægtede forbindelser som nociceptin analoger og ORL1-ligander til behandling af smerte
|
|
EP1387821A2
(en)
|
2001-05-10 |
2004-02-11 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
WO2002102783A1
(en)
|
2001-06-19 |
2002-12-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6740641B2
(en)
|
2001-07-27 |
2004-05-25 |
Euro-Celtique, S.A. |
Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
|
|
WO2003020699A2
(en)
|
2001-08-30 |
2003-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
AR036492A1
(es)
|
2001-09-06 |
2004-09-15 |
Schering Corp |
Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
|
|
US7169788B2
(en)
|
2001-10-30 |
2007-01-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
JP2005511581A
(ja)
|
2001-11-07 |
2005-04-28 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害剤
|
|
DE60222302T2
(de)
|
2001-12-06 |
2008-05-29 |
Merck & Co., Inc. |
Inhibitoren von mitotischem kinesin
|
|
AU2003212882A1
(en)
|
2002-02-01 |
2003-09-02 |
Euro-Celtique S.A. |
2 - piperazine - pyridines useful for treating pain
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
US6974818B2
(en)
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
|
CA2478827A1
(en)
|
2002-03-11 |
2003-09-18 |
Takeda Chemical Industries, Ltd. |
Remedies for sex hormone-dependent disease
|
|
EP1494676B1
(en)
|
2002-04-08 |
2013-05-08 |
Merck Sharp & Dohme Corp. |
Fused quinoxaline derivatives as inhibitors of akt activity
|
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
|
DE60318198T2
(de)
|
2002-05-02 |
2008-12-04 |
Merck & Co., Inc. |
Tyrosinkinase-hemmer
|
|
ES2282647T3
(es)
|
2002-06-14 |
2007-10-16 |
MERCK & CO., INC. |
Inhibidores de cinesina mitotica.
|
|
PT1556354E
(pt)
|
2002-06-28 |
2008-04-17 |
Euro Celtique Sa |
Derivados de piperazina úteis como agentes terapêuticos para o tratamento da dor
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
CA2494372C
(en)
|
2002-08-15 |
2013-05-28 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
US20050101581A1
(en)
|
2002-08-28 |
2005-05-12 |
Reading Christopher L. |
Therapeutic treatment methods 2
|
|
CA2496867A1
(en)
|
2002-08-28 |
2004-03-11 |
Hollis-Eden Pharmaceuticals, Inc. |
Therapeutic treatment methods
|
|
US7157462B2
(en)
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
ES2298570T3
(es)
|
2002-10-23 |
2008-05-16 |
Pantarhei Bioscience B.V. |
Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer.
|
|
EP1558609A4
(en)
|
2002-10-30 |
2008-05-28 |
Merck & Co Inc |
KINASE INHIBITORS
|
|
US7202259B2
(en)
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
AU2003293555A1
(en)
|
2002-12-17 |
2004-07-29 |
Schering Corporation |
17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
|
JP2006515623A
(ja)
|
2003-01-13 |
2006-06-01 |
セダーズ−シナイ メディカル センター |
化学療法剤としてのパリカルシトール
|
|
TWI330079B
(en)
|
2003-01-15 |
2010-09-11 |
Synta Pharmaceuticals Corp |
Treatment for cancers
|
|
EP1633316A4
(en)
|
2003-05-06 |
2008-04-02 |
Human Genome Sciences Inc |
ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
|
|
US20050020546A1
(en)
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
AR044688A1
(es)
|
2003-06-12 |
2005-09-21 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento del dolor
|
|
PL1867644T3
(pl)
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
|
|
SI1867644T1
(sl)
|
2003-07-24 |
2009-10-31 |
Euro Celtique Sa |
Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
|
|
US7071333B2
(en)
|
2003-07-30 |
2006-07-04 |
Bristol-Myers Squibb Company |
Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
|
|
SI1648880T1
(sl)
|
2003-08-01 |
2010-05-31 |
Euro Celtique Sa |
Terapevtska sredstva uporabna za zdravljenje bolečine
|
|
CN1842515A
(zh)
|
2003-08-27 |
2006-10-04 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶抑制剂
|
|
JP4630871B2
(ja)
|
2003-09-22 |
2011-02-09 |
ユーロ−セルティーク エス．エイ． |
疼痛を治療するのに有用な治療薬
|
|
HRP20080492T3
(hr)
|
2003-09-22 |
2008-11-30 |
Euro-Celtique S.A. |
Fenil-karboksamidni spojevi korisni za liječenje boli
|
|
PL1673092T3
(pl)
|
2003-10-17 |
2008-01-31 |
4 Aza Ip Nv |
Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu
|
|
US7445794B1
(en)
|
2004-04-29 |
2008-11-04 |
The Regents Of The University Of Colorado |
Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
|
|
US20060003950A1
(en)
|
2004-06-30 |
2006-01-05 |
Bone Care International, Inc. |
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
|
US20060030608A1
(en)
|
2004-08-04 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anti aromatase compounds pharmaceutical compositions and uses thereof
|
|
GB0418900D0
(en)
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
|
KR101363563B1
(ko)
|
2004-09-10 |
2014-02-14 |
자고텍 아게 |
활성성분의 부위 및 시간 제어적 위장관 방출 정제
|
|
AR051597A1
(es)
|
2004-11-01 |
2007-01-24 |
Merck & Co Inc |
Moduladores de los receptores de estrogeno
|
|
EP1674479A1
(en)
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
|
WO2006081152A2
(en)
|
2005-01-24 |
2006-08-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
AU2006239219A1
(en)
|
2005-04-27 |
2006-11-02 |
University Of Florida Research Foundation, Inc. |
Materials and methods for enhanced degradation of mutant proteins associated with human disease
|
|
CA2611735A1
(en)
|
2005-04-28 |
2006-11-02 |
The Regents Of The University Of Colorado |
Therapeutic bifunctional compounds
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
CN101267779A
(zh)
|
2005-07-27 |
2008-09-17 |
福罗里达大学研究基金会有限公司 |
使用热休克治疗眼睛疾病
|
|
AU2007232297B2
(en)
|
2006-04-03 |
2012-09-20 |
Msd Italia S.R.L. |
Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
|
|
CA2654174A1
(en)
|
2006-06-02 |
2008-04-03 |
Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services |
Rna nanoparticles and nanotubes
|
|
US20080004286A1
(en)
|
2006-06-30 |
2008-01-03 |
Schering Corporation |
Method of Using Substituted Piperidines that Increase P53 Activity
|
|
MX2009000285A
(es)
|
2006-06-30 |
2009-06-08 |
Schering Corp |
Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
US20080051375A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
|
CN101528308A
(zh)
|
2006-08-25 |
2009-09-09 |
库伽尔生物科技公司 |
治疗癌症的方法和组合物
|
|
EP2081964A4
(en)
|
2006-10-12 |
2012-07-11 |
Univ Johns Hopkins |
ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
|
|
US20100168228A1
(en)
|
2006-10-13 |
2010-07-01 |
Reliance Life Sciences Pvt. Ltd. |
Novel chemotherapeutic agents against inflammation and cancer
|
|
EP2805945B1
(en)
|
2007-01-10 |
2019-04-03 |
MSD Italia S.r.l. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
|
EP2120900A2
(en)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Combination of lbh589 with other therapeutic agents for treating cancer
|
|
WO2008109740A2
(en)
|
2007-03-06 |
2008-09-12 |
Colby Pharmaceutical Company |
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
|
|
US20090124587A1
(en)
|
2007-07-12 |
2009-05-14 |
Auerbach Alan H |
METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
ES2548131T3
(es)
|
2008-01-08 |
2015-10-14 |
Merck Sharp & Dohme Limited |
Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
|
|
EP2276767B1
(en)
|
2008-03-31 |
2014-05-07 |
Genentech, Inc. |
Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
|
|
PT2278975T
(pt)
|
2008-05-07 |
2016-11-08 |
Cardioxyl Pharmaceuticals Inc |
Novos compostos de nitroso como dadores de nitroxilo e métodos de utilização dos mesmos
|
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
|
JP5804395B2
(ja)
|
2011-02-03 |
2015-11-04 |
ポップ テスト オンコロジー エルエルシー |
診断と治療のためのシステムおよび方法
|
|
US9314473B2
(en)
|
2011-02-03 |
2016-04-19 |
Pop Test Oncology Limited Liability Company |
System and method for diagnosis and treatment
|
|
AU2013323861C1
(en)
*
|
2012-09-26 |
2024-05-02 |
Aragon Pharmaceuticals, Inc. |
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
US9797771B2
(en)
|
2013-03-21 |
2017-10-24 |
Isp Investments Inc. |
Diacetylene film sensitized with photoinitiator and applications of the film
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
US9808472B2
(en)
*
|
2013-08-12 |
2017-11-07 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
|
US9987275B2
(en)
|
2014-04-23 |
2018-06-05 |
The Brigham And Women's Hospital, Inc. |
Targeting PARP1 for treatment of TSC and cancers
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
WO2016094391A1
(en)
|
2014-12-08 |
2016-06-16 |
Myriad Genetics, Inc. |
Methods and materials for predicting response to niraparib
|
|
US9598459B2
(en)
|
2015-08-03 |
2017-03-21 |
Pop Test Oncology Llc |
Pharmaceutical compositions and methods
|
|
FI3490560T3
(fi)
|
2016-07-29 |
2025-02-27 |
Janssen Pharmaceutica Nv |
Niraparibi käytettäväksi eturauhassyövän hoitomenetelmässä
|
|
US11702443B2
(en)
|
2016-10-04 |
2023-07-18 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
US11040037B2
(en)
|
2016-10-04 |
2021-06-22 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
JOP20190244A1
(ar)
|
2017-04-13 |
2019-10-13 |
Janssen Pharmaceutica Nv |
تركيبة علاجية لسرطان البروستاتا
|
|
JOP20200072A1
(ar)
|
2017-10-11 |
2020-04-29 |
Janssen Oncology Inc |
طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين
|